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Abstract 
Background: The COVID-19 is a family of large enveloped non-segmented positive-sense RNA viruses which was 
first reported in December 2019 in Wuhan, China with a cluster of unexplained pneumonia. Although various 
medications have been tried to manage the COVID-19 pandemic, there is no exclusive medication or vaccine so far. 
In this study, we aimed to focus on the effectiveness of Hydroxychloroquine + Kaletra (lopinavir/ritonavir) versus 
Hydroxychloroquine + Sofosbuvir in patients hospitalized with COVID-19 to given the urgent need for an effective 
drug against SARS-CoV-2 in the current pandemic context. 
Materials and Methods: Fifty-four eligible patients with moderate to severe COVID-19 symptoms, according 
to the WHO criteria entered the study. Patients were randomized into two treatment groups. Thirty-two patients 
received Hydroxicholoroquine (400 mg stat) and Kaletra (400/100 mg q 12 h) as a control group (group A) and 
the trial group of 22 patients, received Hydroxicholoroquine (200 mg q 12 h) plus Sofosbuvir (400 mg daily) 
(group B) for a period of 7 to 14 days. Eventually, collected data included demographic characteristics, 
underlying diseases, clinical symptoms, laboratory data, and mortality were analyzed. 
Results: There was no significant difference in age, sex, and underlying diseases between the two groups. 
There was no significant statistical difference between the two groups on the seventh day of treatment in 
terms of cough relief, leukocyte count, and improvement of lymphopenia however in terms of the time of 
defervescence of fever, there was a significant difference between the two groups. 
Conclusion: Therefore, it can be said that our study is one of the first studies in the world to evaluate the 
effectiveness of sofosbuvir in the treatment of patients with COVID-19. According to our results, although 
Kaletra was assumed as an effective therapy, its superiority over Sofosbuvir was confined to the earlier 
effervescence of the 7-day fever and sofosbuvir can be used as an effective treatment, especially in patients 
with underlying heart disease who are at risk for arrhythmias with Kaletra. 
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Introduction 
After the emergence and spread of the newly 
discovered corona virus infection in China in 
December 2019, other countries, including Iran, were 
also faced with the prevalence of this virus. Until 
July 6, 2020, 240438 cases had been confirmed in 
Iran and 11327790 had been documented globally.  
Corona virus disease 2019 (COVID-19) has reached 
pandemic status and an unknown animal may be 
responsible for spreading this new human pathogen 
coronavirus. The clinical manifestations of the 
disease consist of malaise, dry cough, shortness of 
breath and respiratory distress. Thus, six various 
strains of Human coronaviruses (HCoVs) have been 
reported, including the the newly emerged 
COVID191. 
Specific drugs may be effective in treatment, 
depending on the biophysical information and the 
genome of individual coronaviruses, such as 
inhibitors of specific viral enzymes, siRNA 
molecules involved in the viral replication cycle, and 
inhibitors of host cell proteases2. 
Sofosbuvir and Ribavirin are conventionally used 
against RNA dependent RNA polymerase (RdRp) of 
the hepatitis C virus (HCV). These drugs are 
nucleotides derivatives that compete with 
physiological nucleotides for the RdRp active site3.  
Many antiviral drugs have been tested for safety in 
preventing SARS-CoV-2 replication in cell cultures. 
Hydroxychloroquine (HCQ) is one of the disease-
modifying antirheumatic drugs (DMARDs).The 
DMARDs are widely used for curing many 
rheumatic diseases and show strong 
immunomodulatory capacity,which prevents 
inflammation flare-ups and organ damage4. 
Even though many of these drugs show anti 
coronavirus activity in vivo and/or in vitro, their 
pharmacodynamic and pharmacokinetic properties, 
in addition to their side effect profile,but more 
careful clinical trials are required to validate these 
new specific drugs. 
In general, there are no specific antiviral drugs or 
vaccines for 2019-nCoV. All of the drug options 
come from experience treating SARS, MERS or 
some other recent influenza virus. Active 
symptomatic support remains key to treatment. The 
aforementioned drugs could be helpful, but further 
confirmation of their their efficacy is required2. 
The newly emerged corona virus is a health concern 
for people all around the word .The present study 
aimed to investigate the efficacy and adverse effects of 
two groups of drugs A: (Hydroxychloroquine 
+kaletra) and B: (Hydroxychloroquine+sofosbuvir) in 
the treatment of SARA-COV2: an open label phase III 
among patients who had positive PCR tests or who 
had CT scans compatible with this infection. The 
medications were administed to each group of patients 
for at least 7 days. 
Methods 
This clinical trial was conducted at a referral hospital 
for Covid-19 patients in Tehran, Iran, between March 
and April 2020. The inclusion criteria in our study 
were as follows Age above 18, hospitalized patients 
with fever (Oral temperature ≥ 38 ℃) and at least one 
of the following: a respiratory rate more than 24/min 
or an O2 Saturation level less than 93% or the PaO2/ 
FiO2 ratio lower than 300. Patients had to have a 
confirmed PCR for the nuclide acid of SARS-COV-2 
in a nasopharyngeal swab specimen or a chest lung CT 
scan compatible with COVID-19 patterns. The 
exclusion criteria were dissatisfaction with being 
included in or continuing the study, having a known 
allergic reaction to interventional drugs, pregnancy or 
breastfeeding, any prior experimental treatments for 
COVID-19, a heart rate less than 60/min, taking 
amiodarone, evidence of multiorgan failure, requiring 
mechanical ventilation at the screening or an eGFR of 
less than 50 ml/min. Fifty-four eligible patients with 
moderate to severe COVID-19 symptoms, according 
to the WHO criteria, were enrolled in the study. 
Patients were randomized into two treatment groups. 
Thirty-two patients made up the control group (group 
A) who received Hydroxicholoroquine (400 mg stat) 
and Kaletra (400/100 mg q 12 h) and the trial group 
(group B) consisted of 22 patients, who were 
administered Hydroxicholoroquine (200 mg q 12 h) 
plus Sofosbuvir (400 mg daily). 
Collected data included demographic characteristics 
and underlying diseases, clinical symptoms such as 
fever, cough, myalgia at the time of admission and on 
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the seventh day of hospitalization, as well as 
laboratory data such as PCR test results, the number 
of leukocytes and lymphocytes on the day of 
admission and on the seventh day of hospitalization. 
Mortality was also compared between the two 
groups. Data were analyzed with IBM SPSS software 
version 23. Based on our pilot study criteria for the 
improvement of clinical symptoms and a statistical 
power of 80% with a type one error of 5%, a sample 
size of 22 patients for each group was calculated. 
The Independent t-test was used to compare means 
and Chi-two was utilized to assess frequencies. 
These data are presented in tables 1 to 3. This study 
has been approved by the ethics committee of Shahid 
Beheshti University of Medical Sciences in Tehran, 
Iran (IR.SBMU.RETECH.REC.1399.557). 
Results 
A total of 32 patients with moderate to severe 
symptoms of COVID-19 in the control group 
received Hydroxicholoroquine and Kaletra (group A) 
(15 male and 17 female). In comparison, 22 patients 
(14 male and 8 female) were treated with 
Hydroxicholoroquine and Sofosbuvir (group B). 
There were no significant differences in terms of age 
and sex between the two groups. Thirty-one percent 
of patients in group A and thirty-six percent of 
patients in group B were diabetics, which was not 
statistically significant. Fifty-nine percent of patients 
in group A and fifty percent of patients in group B 
suffered from other underlying diseases (Table-1). 
The patients in group A and half of those in group B 
had a positive nasopharyngeal swab test (which was 
statistically significant). The spiral chest CT scan of 
all patients who were enrolled in our study were 
compatible with COVID-19 patterns. Sixty-five 
percent of patients in group A and fifty-nine percent 
of patients in group B had a fever at the time of 
admission. (not statistically significant). Other 
clinical manifestations of patients in both groups at 
the time of admission are shown in Table 2. The 
numbers of leukocytes and lymphocytes at the time 
of admission were also compared between the two 
groups, the results of which were not statistically 
significant (Table-2). 
In the follow-up of patients, sixty-eight percent of 
group A and seventy-two percent of group B had 
lymphopenia on the seventh day. Therefore, there was 
no statistically significant difference between the two 
groups in terms of the improvement of lymphopenia 
on the seventh day post-treatment. All the patients in 
group A and eighty-six percent of those in group B 
had no fever on day seven of treatment. Therefore, in 
terms of the time of defervescence of fever, there was 
a significant difference between the two groups. There 
were no significant statistical differences between the 
two groups on the seventh day of treatment in terms of 
cough relief and leukocyte count (Table-3). The 
number of patients from groups A and B who 
withdrew from the study were 3 and 2, respectively 
(Table-3). The most common side effect in both 
groups was a headache and the difference was not 
statistically significant between the two groups (Table-
3). 
Discussion 
The COVID-19 is a family of large enveloped non-
segmented positive-sense RNA viruses first reported 
in December 2019 in Wuhan, China, presenting with a 
cluster of cases of unexplained pneumonia. It soon 
turned into a global health concern and, as of June 30, 
2020, COVID-19 has resulted in 7553182 confirmed 
cases and 423349 confirmed deaths5. The typical 
clinical picture varies from mild acute respiratory 
symptoms to severe pneumonia with respiratory 
failure and septic shock; the severity of symptoms 
depends on the level of each individual's immunity 
and comorbidities6,7.  
Although various medications have been tried to 
manage the COVID-19 pandemic, according to the 
World Health Organization (WHO), the Centers for 
Disease Control and Prevention (CDC) and the U.S. 
Food and Drug Administration (FDA), no medication 
or vaccine has been sufficiently effective in its 
treatment8–10. 
Considering the urgent need for an effective drug 
against SARS-CoV-2 in the current pandemic, we 
aimed to focus on the effectiveness of 
Hydroxychloroquine+Kaletra (lopinavir/ritonavir) 
versus Hydroxychloroquine+Sofosbuvir in 
hospitalized patients with COVID-19. We evaluated 
32 patients administered Hydroxychloroquine+Kaletra 
(lopinavir/ritonavir) and 22 patients treated with 
Hydroxychloroquine+Sofosbuvir. Regarding age, sex 
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and underlying commodities, no significant 
differences were observed. Our results revealed that 
Hydroxychloroquine+Kaletra was considerably more 
effective when it came to decreasing 7-day fever 
compared to Hydroxychloroquine+Sofosbuvir 
(P=0.03). However, we did not find statistically 
significant differences in terms of day-7 cough, 
improvement in lymphopenia and leukocytopenia, 
mortality, or adverse effects, such as headache, 
between the two study groups. 
It is noteworthy that, early in the COVID-19 
pandemic, Hydroxychloroquine (HCQ) had earned a 
reputation as a potentially promising inhibitor of 
SARS-CoV-2 replication in cell cultures. HCQ 
increases the intracellular pH and inhibits the 
lysosomal activity in antigen-presenting cells (APCs) 
like plasmacytoid dendritic cells (pDCs) and B cells, 
leading to the prevention of antigen processing and 
major histocompatibility complex (MHC) class II-
mediated autoantigen presentation to T cells, which 
eventually leads to the reduction of T cell activation, 
differentiation, and expression of costimulatory 
proteins and cytokines produced by B and T cells. 
Additionally, it suppresses the toll-like receptors 
(TLR7 and TLR9) signaling and interferes with the 
interaction between cytosolic DNA and the nucleic 
acid sensor cyclic GMP-AMP (champ) synthase 
(CGAS), both of which attenuate the inflammatory 
cytokine cascade4 ,11–16. 
Later, a huge number of attempts were made to 
develop other antiviral drugs. Favilavir was first 
approved by the national medical products 
administration of China on February 18, 2020, 
followed by other antivirals including Sofosbuvir, 
IDX184, Ribavirin, Remdisivir, Guanosine 
triphosphate (GTP), Uracil triphosphate (UTP), 
Cinnamaldehyde, Thymoquinone, and 
Lopinavir/ritonavir17. Lopinavir is a member of the 
family of protease inhibitors and ritonavir, which is 
commonly used against the human immunodeficiency 
virus (HIV), acts as a booster.There is evidence 
suggesting the anti-COVID-19 activity of 
Lopinavir/ritonavir18.  
Chu et al. evaluated the three-week clinical prognosis 
and virological outcomes of forty-one patients treated 
with a combination of lopinavir/ritonavir and ribavirin 
in comparison to 111 patients administered ribavirin 
alone. Their results revealed that patients treated with 
Table 1: Demographic characteristics and underlying diseases in the two groups treated for Covid-19. 
 Group A (n=32) Group B (n=22) p value 
Age (year) 60 ± 13 53 ± 15 0.09 
Gender (M/F) 15/17 14/8 0.2 
Diabetic  31 % 36 % 0.7 
Other underlying diseases 59 % 50 % 0.6 
 
 Table 2: Clinical presentations and laboratory data of patients in the two groups at the time of admission. 
 Group A (n=32) Group B (n=22) p value 
Fever  65 % 59 % 0.7 
Weakness 53 % 54 % 1 
Cough 84 % 72 % 0.3 
Malaise 59 % 68 % 0.6 
PCR positive 100 % 50 % P<0.001 
WBC 8260 ± 4800 7400 ± 3200 0.5 
Lymphocyte 1842 ± 2232 1912 ± 1432 0.7 
 
 Table 3: Mortality, side effects and day-7 clinical findings in the two groups after treatment. 
 Group A (n=32) Group B (n=22) p value 
Mortality (patients) 3 2 1 
Lymphocytopenia  68% 72% 1 
Anemia  0 9 % 0.1 
Leukocytopenia  34% 31% 1 
Headache side-effect 25% 36% 0.4 
Day-7 fever 0 14% 0.03 
Day-7 cough 12% 4% 0.3 
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lopinavir/ritonavir and ribavirin had a lower risk of 
adverse clinical outcomes such as acute respiratory 
distress syndrome (ARDS) or death. Furthermore, 
the prevalence of steroid usage and nosocomial 
infections was less evident in patients initially treated 
with lopinavir/ritonavir, and these patients had a 
decreasing viral load and rising peripheral 
lymphocyte count19. Similarly, Chan et al. conducted 
a retrospective matched cohort study to investigate 
the effectiveness of Kaletra. They evaluated 75 
patients with severe acute respiratory syndrome 
treated with lopinavir/ritonavir as either initial 
treatment or rescue treatment in addition to standard 
treatment compared with matched cohorts of 634 and 
343 patients, respectively. Their results revealed that 
the initial therapy of lopinavir/ritonavir was 
associated with better clinical outcomes leading to a 
reduction in the overall death rate, intubation rate and 
methylprednisolone dosage20.There are also other 
reports confirming the promising role of Kaletra, 
including a study by Elise Klement-Frutos et al. 
which demonstrated the effectiveness of Kaletra in 
decreasing the SARS-CoV-2 load and preventing the 
secondary immune-related severe evolution in early 
presenting non-severe patients21 or another study 
which revealed the superiority of triple therapy with 
lopinavir/ritonavir [400 mg/100 mg q12h], ribavirin 
[400 mg q12h], interferon beta1b [8 million IU x 3 
doses q48h] (n= 86) compared to lopinavir/ritonavir 
alone (n=41) in shortening the duration of viral 
shedding and hospital stay in patients with mild-to-
moderate COVID-1922.  
However, there are reports with disappointing 
results. In one randomized, controlled, open-label 
trial of hospitalized adults, the patients were 
randomized into lopinavir/ritonavir 400 mg/100 mg 
PO BID for 14 days added to standard care (n=99) or 
standard care alone (n=100). The results did not 
confirm the superiority of lopinavir/ritonavir in terms 
of time to clinical improvement or the mortality 
rate23. In another study, the effectiveness of 
lopinavir/ritonavir or umifenovir monotherapy was 
compared to standard care in patients with mild-to-
moderate COVID-19. Their results did not show a 
statistical difference between the two treatment 
groups24. 
On the other hand, Sofosbuvir was approved as an 
antiviral agent against the hepatitis C virus (HCV) 
nonstructural protein 5 (NS5B) RdRp in 2013 with a 
confirmed potential against other viruses, such as the 
Zika virus. It is also hypothesized that the SARS-CoV-
2 infection could also be susceptible to Sofosbuvir25,26. 
Limited studies are focusing on the efficacy of 
Sofosbuvir, for instance, an investigation by Abdo et 
al, who made a model for COVID-19 RdRp by 
sequence analysis, modeling and docking. 
Consequently, the HCoV RdRp model was targeted by 
anti-polymerase drugs, including Sofosbuvir and 
Ribavirin. Their results indicated that Sofosbuvir, 
IDX-184, Ribavirin and Remidisvir could be deemed 
effective drugs against COVID-193.  
Additionally, there are ongoing clinical trials 
evaluating Sofosbuvir efficacy, such as one study 
comparing Sofosbuvir 400 mg in combination with 
Vepastavir 100 mg as an add-on treatment in addition 
to standard treatment26. Moreover, there is an open-
label non-randomized parallel clinical that is being 
conducted in Iran to compare the effectiveness of the 
combination of Daclatasvir+Sofosbuvir with Ribavirin 
in COVID-19 patients with severe symptoms. This 
clinical trial is currently in process27. 
Therefore, it can be stated that our study is one of the 
first studies in the world to evaluate the effectiveness 
of sofosbuvir in the treatment of patients with 
COVID-19. In our study, we compared the 
effectiveness of (Hydroxychloroquine+Kaletra) 
compared to (Hydroxychloroquine+Sofosbuvir). 
According to our results, although Kaletra had been 
considered an effective treatment, its superiority over 
Sofosbuvir was confined to the earlier effervescence 
of the 7-day fever. 
Of note, the main limitation of our study was the lack 
of a control group which might have confound the 
appropriate interpretation. To determine the efficacy 
and safety of anti-viral drugs, more adequately 
powered randomized clinical trials need to be 
conducted. 
Conclusion 
There is insufficient evidence to recommend a specific 
drug for COVID-19 outside of research studies. All of 
the therapeutic options have originated from previous 
experiences with SARS, MERS and recent variants of 
the influenza virus. However, the way to recognize 
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therapeutic options is, and ancillary studies with 
greater sample size are needed to confirm the 
efficacy of the current drugs. 
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